Get a full analysis report for any ticker →

Stock Upgrades & Downgrades

Wall Street upgrades, downgrades, and analyst rating changes with independent commentary. Updated daily from active coverage.

By Basis Report editorial deskReviewed by Basis Report methodology teamMethodology
HBMAnalysis

TSX Approves Hudbay 5% Buyback; Barclays Goes Overweight

Hudbay Minerals secured TSX approval to repurchase up to 5% of its outstanding shares while Barclays initiated coverage with an Overweight rating, supported by 27.3% revenue growth and $546M in trailing free cash flow. The bull case is coherent at a medium confidence level, but GuruFocus values the stock at $9.84 against a $31.87 trading price and the consensus analyst target implies near-zero upside from current levels.

ADTAnalysis

ADT Insiders Buy as Apollo Unloads 102M Shares

Apollo Management entities distributed roughly 102 million ADT shares at $7.25 per share in a May 2026 secondary offering, only for ADT's own director and two EVPs to buy shares in the open market below that price days later. The split between institutional exit and insider accumulation against a backdrop of three consecutive EPS beats makes ADT worth watching, though the Apollo supply overhang limits near-term upside.

CYTKAnalysis

CYTK Surges 20% on HCM Data; Offering Filed, Execs Sell

Cytokinetics shares jumped roughly 20% on May 5 after an HCM trial outcome pushed the stock to two-year highs, but the company immediately filed two securities offering prospectuses and executives collectively sold $8.05 million in shares with zero open-market purchases. The clinical momentum in aficamten is real, but the simultaneous combination of dilutive equity issuance and coordinated insider monetization at peak prices warrants skepticism toward the bullish headline narrative.

ELFAnalysis

ELF Executives Sell $13M as Stock Slides to 52-Week Low

Six e.l.f. Beauty executives sold more than $10 million in shares on a single day in late April 2026, just 72 hours after receiving equity grants, as part of a 90-day insider selling pattern totaling $13.32 million against $0.46 million in purchases. The stock has since fallen to a 52-week low, now trading at $55.38, below every insider transaction price recorded over the period including the sole purchase, pointing to a bearish near-term setup despite an analyst consensus target of $91.60.

JBLUAnalysis

JetBlue Is Losing $1.2 Billion a Year But Trading Above Every Analyst Target — The Takeover Explains Why

JetBlue is granting United Airlines physical gate access at JFK's Terminal 6 and enabling cross-network booking with cash or points, mirroring the operational integration playbook airlines run before acquisitions. The stock trades at $5.60 versus a $4.49 consensus target because analysts are modeling a standalone turnaround while the market is pricing takeover optionality that the accelerating Blue Sky partnership makes more plausible by the quarter.